Cutting-edge investment ideas in the Biotechnology and Pharmaceutical Industry.  REGISTER NOW to receive $10 worth of FREE credit.  This offer is valid for limited time only.
Cart

ACCURACY OF OPINIONS
80% - Correct
20% - Incorrect
 

RECENT NEWS ON COVERED STOCKS  

ISPH
click here

ACOR
click here

BSTC
click here

DDSS
click here

OPTR
click here

New BioMedicine
Event-based Healthcare Investment Reports
Upcoming Event Reports
Listed below are reports of upcoming events . You can use the advance search option to narrow down your search.
1-5 of 85
Sort by Company Name | Report Date | Market Cap | Estimated Peak Sales
Allos Therapeutics, Inc. (ALTH) - Folotyn for Non-Small Cell Lung Cancer (NSCLC) patients, who have failed at least one prior chemotherapy regimen (Phase IIb)

Preliminary data from the Phase IIb trial of Folotyn, designed for the treatment of non-small cell lung cancer (

Allos Therapeutics, Inc. ( ALTH ) - UPCOMING EVENT(,4,2010) - February 05, 2010 - PDF - Price: $20.00 - Add to Cart »

OSI Pharmaceuticals, Inc. (OSIP) - Tarceva as a maintenance therapy for advanced (metastatic) Non-Small Cell Lung Cancer (NSCLC) patients (FDA Approval)

FDA approval of Tarceva as a maintenance therapy for non-small cell lung cancer (NSCLC) patients, who have not e

OSI Pharmaceuticals Inc. ( OSIP ) - UPCOMING EVENT(18,4,2010) - February 04, 2010 - PDF - Price: $20.00 - Add to Cart »

Infinity Pharmaceuticals, Inc. (INFI) - Retaspimycin for Tarceva-failed non-small cell lung cancer/NSCLC (Phase II - Final data)

Final data from the Phase II portion of the Phase I/II trial of Retaspimycin for Tarceva-failed metastatic non-small

Infinity Pharmaceuticals, Inc. ( INFI ) - UPCOMING EVENT(,4,2010) - January 22, 2010 - PDF - Price: $20.00 - Add to Cart »

Pharmasset, Inc. (VRUS) - RG7128 for Hepatitis C Virus (HCV) Infection (Phase IIb)

present the preliminary data from the Phase IIb trial of RG7128 (formerly known as R7128), designed for the treatment

Pharmasset, Inc. ( VRUS ) - UPCOMING EVENT(,4,2010) - January 21, 2010 - PDF - Price: $20.00 - Add to Cart »

Medivation, Inc. (MDVN) - Dimebon for mild-to-moderate Alzheimer's Disease/AD (Phase III)

Top-line data from the Phase III CONNECTION trial of Dimebon for the treatment of mild-to-moderate Alzheimer's diseas

Medivation, Inc. ( MDVN ) - UPCOMING EVENT(,4,2010) - January 19, 2010 - PDF - Price: $20.00 - Add to Cart »
Prev
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17 
Next
1-5 of 85
More Information ©Copyright 2009 New Bio Medicine, LLC. All Right Reserved. Privacy Policy